Discoid Lupus Erythematosus
contact information:
Nicole Bisby or visit www.clinicaltrials.gov (Reference # NCT01466725) 202.741.2437
< back to clinical trials list
A Phase 2, pilot, multicenter, randomized, placebo-controlled sequential, ascending dose study to
characterize the safety, tolerability, pharmacokinetic and pharmacodynamic activity of CC-930 in subjects with recalcitrant Discoid Lupus Erythematosus (DLE).
The purpose of the study is to assess if CC-930 is safe and tolerable in treating subjects with
Discoid Lupus Erythematosus. Pharmacokinetic and pharmacodynamics will also be evaluated.
contact information:
Nicole Bisby or visit www.clinicaltrials.gov (Reference # NCT01466725) 202.741.2437
< back to clinical trials list
ABOUT SSL CERTIFICATES |